Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study

Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carni...

Full description

Saved in:
Bibliographic Details
Published inTranslational psychiatry Vol. 9; no. 1; p. 19
Main Authors Cao, Bing, Wang, Dongfang, Pan, Zihang, Brietzke, Elisa, McIntyre, Roger S., Musial, Natalie, Mansur, Rodrigo B., Subramanieapillai, Mehala, Zeng, Jing, Huang, Ninghua, Wang, Jingyu
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 17.01.2019
Nature Publishing Group
Subjects
101/58
692/53/2421
692/699/476/1799
Adult
Behavioral Sciences
Bioenergetics
Biological Psychology
Biomarkers - blood
Carnitine - analogs & derivatives
Carnitine - blood
Case-Control Studies
China
Chromatography, Liquid
Energy Metabolism
Female
Humans
Logistic Models
Male
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Neurosciences
Pharmacotherapy
Psychiatry
Schizophrenia
Schizophrenia - blood
Schizophrenia - metabolism
Schizophrenia - therapy
Tandem Mass Spectrometry
China
Online AccessGet full text
ISSN2158-3188
2158-3188
DOI10.1038/s41398-018-0353-x

Cover

Abstract Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carnitine levels within well-characterized plasma samples of adults with schizophrenia and healthy controls using liquid chromatography-mass spectrometry (LC-MS). Subjects with schizophrenia were measured at baseline and after 8 weeks of treatment. A total of 225 subjects with schizophrenia and 175 age- and gender-matched healthy controls were enrolled and 156 subjects completed the 8-week follow-up. With respect to plasma acyl-carnitines, the individuals with schizophrenia at baseline showed significantly higher levels of C4-OH (C3-DC) and C16:1, but lower concentrations of C3, C8, C10, C10:1, C10:2, C12, C14:1-OH, C14:2, and C14:2-OH when compared with healthy controls after controlling for age, sex, body mass index (BMI), smoking, and drinking. For the comparison between pretreatment and posttreatment subjects, all detected acyl-carnitines were significantly different between the two groups. Only the concentration of C3 and C4 were increased after selection by variable importance in projection (VIP) value >1.0 and false discovery rate (FDR) q value <0.05. A panel of acyl-carnitines were selected for the ability to differentiate subjects of schizophrenia at baseline from controls, pre- from post-treatment, and posttreatment from controls. Our data implicated acyl-carnitines with abnormalities in cellular bioenergetics of schizophrenia. Therefore, acyl-carnitines can be potential targets for future investigations into their roles in the pathoetiology of schizophrenia.
AbstractList Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carnitine levels within well-characterized plasma samples of adults with schizophrenia and healthy controls using liquid chromatography-mass spectrometry (LC-MS). Subjects with schizophrenia were measured at baseline and after 8 weeks of treatment. A total of 225 subjects with schizophrenia and 175 age- and gender-matched healthy controls were enrolled and 156 subjects completed the 8-week follow-up. With respect to plasma acyl-carnitines, the individuals with schizophrenia at baseline showed significantly higher levels of C4-OH (C3-DC) and C16:1, but lower concentrations of C3, C8, C10, C10:1, C10:2, C12, C14:1-OH, C14:2, and C14:2-OH when compared with healthy controls after controlling for age, sex, body mass index (BMI), smoking, and drinking. For the comparison between pretreatment and posttreatment subjects, all detected acyl-carnitines were significantly different between the two groups. Only the concentration of C3 and C4 were increased after selection by variable importance in projection (VIP) value >1.0 and false discovery rate (FDR) q value <0.05. A panel of acyl-carnitines were selected for the ability to differentiate subjects of schizophrenia at baseline from controls, pre- from post-treatment, and posttreatment from controls. Our data implicated acyl-carnitines with abnormalities in cellular bioenergetics of schizophrenia. Therefore, acyl-carnitines can be potential targets for future investigations into their roles in the pathoetiology of schizophrenia.
Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carnitine levels within well-characterized plasma samples of adults with schizophrenia and healthy controls using liquid chromatography-mass spectrometry (LC-MS). Subjects with schizophrenia were measured at baseline and after 8 weeks of treatment. A total of 225 subjects with schizophrenia and 175 age- and gender-matched healthy controls were enrolled and 156 subjects completed the 8-week follow-up. With respect to plasma acyl-carnitines, the individuals with schizophrenia at baseline showed significantly higher levels of C4-OH (C3-DC) and C16:1, but lower concentrations of C3, C8, C10, C10:1, C10:2, C12, C14:1-OH, C14:2, and C14:2-OH when compared with healthy controls after controlling for age, sex, body mass index (BMI), smoking, and drinking. For the comparison between pretreatment and posttreatment subjects, all detected acyl-carnitines were significantly different between the two groups. Only the concentration of C3 and C4 were increased after selection by variable importance in projection (VIP) value >1.0 and false discovery rate (FDR) q value <0.05. A panel of acyl-carnitines were selected for the ability to differentiate subjects of schizophrenia at baseline from controls, pre- from post-treatment, and posttreatment from controls. Our data implicated acyl-carnitines with abnormalities in cellular bioenergetics of schizophrenia. Therefore, acyl-carnitines can be potential targets for future investigations into their roles in the pathoetiology of schizophrenia.Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carnitine levels within well-characterized plasma samples of adults with schizophrenia and healthy controls using liquid chromatography-mass spectrometry (LC-MS). Subjects with schizophrenia were measured at baseline and after 8 weeks of treatment. A total of 225 subjects with schizophrenia and 175 age- and gender-matched healthy controls were enrolled and 156 subjects completed the 8-week follow-up. With respect to plasma acyl-carnitines, the individuals with schizophrenia at baseline showed significantly higher levels of C4-OH (C3-DC) and C16:1, but lower concentrations of C3, C8, C10, C10:1, C10:2, C12, C14:1-OH, C14:2, and C14:2-OH when compared with healthy controls after controlling for age, sex, body mass index (BMI), smoking, and drinking. For the comparison between pretreatment and posttreatment subjects, all detected acyl-carnitines were significantly different between the two groups. Only the concentration of C3 and C4 were increased after selection by variable importance in projection (VIP) value >1.0 and false discovery rate (FDR) q value <0.05. A panel of acyl-carnitines were selected for the ability to differentiate subjects of schizophrenia at baseline from controls, pre- from post-treatment, and posttreatment from controls. Our data implicated acyl-carnitines with abnormalities in cellular bioenergetics of schizophrenia. Therefore, acyl-carnitines can be potential targets for future investigations into their roles in the pathoetiology of schizophrenia.
Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29 acyl-carnitine levels within well-characterized plasma samples of adults with schizophrenia and healthy controls using liquid chromatography-mass spectrometry (LC-MS). Subjects with schizophrenia were measured at baseline and after 8 weeks of treatment. A total of 225 subjects with schizophrenia and 175 age- and gender-matched healthy controls were enrolled and 156 subjects completed the 8-week follow-up. With respect to plasma acyl-carnitines, the individuals with schizophrenia at baseline showed significantly higher levels of C4-OH (C3-DC) and C16:1, but lower concentrations of C3, C8, C10, C10:1, C10:2, C12, C14:1-OH, C14:2, and C14:2-OH when compared with healthy controls after controlling for age, sex, body mass index (BMI), smoking, and drinking. For the comparison between pretreatment and posttreatment subjects, all detected acyl-carnitines were significantly different between the two groups. Only the concentration of C3 and C4 were increased after selection by variable importance in projection (VIP) value >1.0 and false discovery rate (FDR) q value <0.05. A panel of acyl-carnitines were selected for the ability to differentiate subjects of schizophrenia at baseline from controls, pre- from post-treatment, and posttreatment from controls. Our data implicated acyl-carnitines with abnormalities in cellular bioenergetics of schizophrenia. Therefore, acyl-carnitines can be potential targets for future investigations into their roles in the pathoetiology of schizophrenia.
ArticleNumber 19
Author Wang, Dongfang
Zeng, Jing
Wang, Jingyu
Huang, Ninghua
Cao, Bing
McIntyre, Roger S.
Musial, Natalie
Brietzke, Elisa
Pan, Zihang
Mansur, Rodrigo B.
Subramanieapillai, Mehala
Author_xml – sequence: 1
  givenname: Bing
  surname: Cao
  fullname: Cao, Bing
  organization: Department of Laboratorial Science and Technology, School of Public Health, Peking University
– sequence: 2
  givenname: Dongfang
  surname: Wang
  fullname: Wang, Dongfang
  organization: Department of Laboratorial Science and Technology, School of Public Health, Peking University
– sequence: 3
  givenname: Zihang
  surname: Pan
  fullname: Pan, Zihang
  organization: Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network
– sequence: 4
  givenname: Elisa
  surname: Brietzke
  fullname: Brietzke, Elisa
  organization: Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Department of Psychiatry, Federal University of São Paulo
– sequence: 5
  givenname: Roger S.
  surname: McIntyre
  fullname: McIntyre, Roger S.
  organization: Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network, Brain and Cognition Discovery Foundation
– sequence: 6
  givenname: Natalie
  orcidid: 0000-0003-1229-4862
  surname: Musial
  fullname: Musial, Natalie
  organization: Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network
– sequence: 7
  givenname: Rodrigo B.
  surname: Mansur
  fullname: Mansur, Rodrigo B.
  organization: Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network
– sequence: 8
  givenname: Mehala
  surname: Subramanieapillai
  fullname: Subramanieapillai, Mehala
  organization: Mood Disorders Psychopharmacology Unit, Toronto Western Hospital, University Health Network
– sequence: 9
  givenname: Jing
  surname: Zeng
  fullname: Zeng, Jing
  organization: Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, Peking University Medical and Health Analysis Center, Peking University
– sequence: 10
  givenname: Ninghua
  surname: Huang
  fullname: Huang, Ninghua
  organization: Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, Peking University Medical and Health Analysis Center, Peking University
– sequence: 11
  givenname: Jingyu
  surname: Wang
  fullname: Wang, Jingyu
  email: wjy@bjmu.edu.cn
  organization: Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, Peking University Medical and Health Analysis Center, Peking University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30655505$$D View this record in MEDLINE/PubMed
BookMark eNqNkVFrFDEUhQep2Fr7A3yRgC--jCabySTjgyCLVaHgiz6HO8md3dTZZEwytdtf3yy72lpQDIQE8p3DuSdPqyMfPFbVc0ZfM8rVm9Qw3qmasrK54PX1o-pkwYSqOVPq6N79uDpL6ZKWJRrFJHtSHXPaCiGoOKm-L9cQwWSM7sb5FQGzHWsD0bvsPJLeheRWHvIcMZEhRJLM2t2EaR3RO3hLgIzBr1yerfMwkiliTcBbMoWU6xwR8gZ9JqkA22fV4wHGhGeH87T6dv7h6_JTffHl4-fl-4vaNJLmGoTlFJUaBtmj6ji2VEoJ2EmUyBuxkB03FqXqgVspqVW9gKG1aC32yiA_rRZ739lPsP0J46in6DYQt5pRvStP78vTpTy9K09fF9G7vWia-w1aU1JHuBMGcPrPF-_WehWudMt5q1hTDF4dDGL4MWPKeuOSwXEEj2FOesFk19CubduCvnyAXoY5lv52VDErA3eqUC_uJ_od5dfnFUDuARNDShEHbVyG7MIuoBv_OSx7oPyfgg6tpsL6Fca70H8X3QIlI9K1
CitedBy_id crossref_primary_10_1016_j_jadr_2021_100261
crossref_primary_10_1371_journal_pone_0245770
crossref_primary_10_3390_biom11050720
crossref_primary_10_1021_acs_jafc_4c05005
crossref_primary_10_3389_fnins_2020_00632
crossref_primary_10_1111_cts_13122
crossref_primary_10_1016_j_psychres_2020_113458
crossref_primary_10_1016_j_neurobiolaging_2019_10_014
crossref_primary_10_3390_biomedicines9111610
crossref_primary_10_1002_bmc_4864
crossref_primary_10_1016_j_jad_2024_09_058
crossref_primary_10_1016_j_biopha_2020_110707
crossref_primary_10_1124_pharmrev_121_000408
crossref_primary_10_1093_cercor_bhae160
crossref_primary_10_3389_fmed_2022_828867
crossref_primary_10_3390_metabo12090850
crossref_primary_10_1016_j_foodres_2022_111171
crossref_primary_10_1134_S1819712423040086
crossref_primary_10_1186_s12888_024_05969_9
crossref_primary_10_1111_imj_16473
crossref_primary_10_20538_1682_0363_2019_4_197_208
crossref_primary_10_3390_metabo11100685
crossref_primary_10_1002_ange_202101007
crossref_primary_10_1007_s11306_022_01909_4
crossref_primary_10_30773_pi_2023_0121
crossref_primary_10_1038_s41398_020_01097_6
crossref_primary_10_3389_fphar_2023_1255501
crossref_primary_10_3390_children10020322
crossref_primary_10_1016_j_euroneuro_2020_09_404
crossref_primary_10_3390_medicina58111509
crossref_primary_10_3390_biom14080914
crossref_primary_10_3390_metabo11010034
crossref_primary_10_31857_S1027813323040088
crossref_primary_10_1002_anie_202101007
crossref_primary_10_1002_aur_3029
crossref_primary_10_1111_pcn_13194
crossref_primary_10_1038_s41398_020_01084_x
crossref_primary_10_1001_jamapsychiatry_2022_4350
crossref_primary_10_1186_s40168_022_01230_1
crossref_primary_10_17816_CP101
crossref_primary_10_3389_fpsyt_2021_777447
crossref_primary_10_3389_fnins_2024_1505153
crossref_primary_10_3390_metabo14020080
crossref_primary_10_1016_j_brainres_2021_147370
crossref_primary_10_1186_s12888_024_05660_z
crossref_primary_10_17816_CP15488
crossref_primary_10_1093_schbul_sbac130
crossref_primary_10_1038_s41398_024_03095_4
crossref_primary_10_3389_fnut_2022_853058
crossref_primary_10_1016_j_ebiom_2024_105455
crossref_primary_10_14336_AD_2024_0434
Cites_doi 10.1194/jlr.D022608
10.1093/schbul/sbq058
10.1016/j.dld.2007.06.013
10.1016/S1388-1981(00)00044-5
10.3390/ijerph15050865
10.1093/oxfordjournals.schbul.a033363
10.1161/CIRCGENETICS.116.001444
10.1373/clinchem.2003.022178
10.1186/1741-7015-11-60
10.1016/j.mam.2004.06.006
10.1097/WNF.0000000000000170
10.1016/j.cmet.2012.04.010
10.1042/bj3610417
10.2337/db12-0466
10.1038/tp.2016.222
10.1111/eci.12609
10.1016/j.jpsychires.2014.02.005
10.1016/j.neuroimage.2013.05.126
10.1371/journal.pmed.0020141
10.1194/jlr.R067629
10.2165/00002512-200623030-00008
10.1096/fj.14-255901
10.1186/cc3742
10.1021/acs.jproteome.7b00279
10.1073/pnas.72.3.883
10.1097/01.pra.0000367773.03636.d1
10.1080/15563650902752376
10.1373/clinchem.2004.043646
10.1074/mcp.M112.021816
10.1074/jbc.M109.032888
10.1194/jlr.M200137-JLR200
10.1016/j.cmet.2007.10.013
10.2337/dc16-0232
10.1002/ddr.21295
10.1016/j.neubiorev.2017.01.029
10.1016/j.neuint.2012.04.008
10.1080/09513590.2017.1290071
10.1080/15622975.2016.1178803
10.1192/apt.bp.115.015610
10.2174/1389201033489829
10.1016/j.clinbiochem.2012.10.006
10.1016/S0014-5793(00)01817-2
10.4239/wjd.v8.i8.390
10.1016/j.schres.2016.09.026
10.1038/tp.2012.143
10.1016/j.plipres.2009.08.004
10.1016/j.mam.2004.06.003
10.1042/BCJ20160164
10.1017/S0007114507705020
10.1016/j.bbamcr.2016.01.023
10.1371/journal.pone.0182761
10.1002/mnfr.201500495
10.1016/S0022-2275(20)37286-2
10.1038/nature08192
ContentType Journal Article
Copyright The Author(s) 2019
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2019
– notice: This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
ADTOC
UNPAY
DOI 10.1038/s41398-018-0353-x
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic


MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2158-3188
ExternalDocumentID 10.1038/s41398-018-0353-x
PMC6336814
30655505
10_1038_s41398_018_0353_x
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
0R~
3V.
53G
5VS
7X7
88E
8FI
8FJ
AAJSJ
AAKDD
ABUWG
ACGFO
ACGFS
ACMJI
ACSMW
ADBBV
ADFRT
AENEX
AFKRA
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
KQ8
LGEZI
LOTEE
M1P
M~E
NADUK
NAO
NXXTH
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
CITATION
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AZQEC
DWQXO
K9.
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
4.4
ADTOC
BAPOH
UNPAY
ID FETCH-LOGICAL-c470t-a5d30e88ff7be893e60777ae97e7e3452793cde78ba3d770d8b5af6deddeb8ce3
IEDL.DBID BENPR
ISSN 2158-3188
IngestDate Sun Oct 26 04:09:03 EDT 2025
Tue Sep 30 16:42:00 EDT 2025
Fri Sep 05 10:31:27 EDT 2025
Tue Oct 07 06:37:17 EDT 2025
Thu Jan 02 22:59:20 EST 2025
Thu Apr 24 22:57:20 EDT 2025
Wed Oct 01 01:39:11 EDT 2025
Fri Feb 21 02:39:06 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c470t-a5d30e88ff7be893e60777ae97e7e3452793cde78ba3d770d8b5af6deddeb8ce3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1229-4862
OpenAccessLink https://www.proquest.com/docview/2168160798?pq-origsite=%requestingapplication%&accountid=15518
PMID 30655505
PQID 2168160798
PQPubID 2041978
ParticipantIDs unpaywall_primary_10_1038_s41398_018_0353_x
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6336814
proquest_miscellaneous_2179409666
proquest_journals_2168160798
pubmed_primary_30655505
crossref_citationtrail_10_1038_s41398_018_0353_x
crossref_primary_10_1038_s41398_018_0353_x
springer_journals_10_1038_s41398_018_0353_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-01-17
PublicationDateYYYYMMDD 2019-01-17
PublicationDate_xml – month: 01
  year: 2019
  text: 2019-01-17
  day: 17
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
PublicationTitle Translational psychiatry
PublicationTitleAbbrev Transl Psychiatry
PublicationTitleAlternate Transl Psychiatry
PublicationYear 2019
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Frye, Melnyk, Macfabe (CR22) 2013; 3
Chace, Kalas, Naylor (CR54) 2003; 49
Kirkpatrick, Miller, Garcia-Rizo, Fernandez-Egea, Bernardo (CR8) 2012; 38
Coskun, Dogan (CR10) 2002; 111
Cuturic, Abramson, Moran, Hardin (CR26) 2010; 16
Signorelli (CR19) 2006; 23
Shi (CR2) 2009; 460
Lai, Ho, Lim, Ho (CR34) 2017; 23
Ensenauer (CR30) 2012; 53
Bene (CR29) 2007; 98
Wang (CR21) 2014; 53
Steiber, Kerner, Hoppel (CR53) 2004; 25
Mutomba (CR40) 2000; 478
Virmani, Binienda (CR41) 2004; 25
Pande (CR42) 1975; 72
Schooneman, Vaz, Houten, Soeters (CR51) 2013; 62
Schonfeld, Wojtczak (CR13) 2016; 57
Cuturic, Abramson, Breen, Edwards, Levy (CR24) 2016; 17
Noland (CR14) 2009; 284
Muoio, Neufer (CR28) 2012; 15
Ciacci (CR20) 2007; 39
Addington, Addington (CR3) 1999; 25
Greenhalgh (CR7) 2017; 179
Vaz, Wanders (CR9) 2002; 361
Wijaya (CR36) 2018; 15
Suvitaival (CR6) 2016; 6
Takizawa (CR35) 2014; 85
Annamalai, Kosir, Tek (CR5) 2017; 8
Waagsbo (CR44) 2016; 46
Cavedon (CR16) 2005; 51
Beckmann (CR39) 2016; 60
Boemer (CR55) 2017; 12
Longo, Frigeni, Pasquali (CR52) 2016; 1863
Ho, Duclos, Hamilton (CR38) 2002; 43
Jones, McDonald, Borum (CR11) 2010; 49
Moos (CR43) 2016; 77
Lheureux, Hantson (CR48) 2009; 47
Lacruz (CR32) 2016; 9
Costa (CR12) 1997; 38
Kerner, Hoppel (CR37) 2000; 1486
Koves (CR50) 2008; 7
Jamilian (CR25) 2017; 33
Liepinsh (CR45) 2016; 473
Saha, Chant, Welham, McGrath (CR1) 2005; 2
Bruno (CR27) 2016; 39
Wong (CR17) 2013; 46
Smeland, Meisingset, Borges, Sonnewald (CR15) 2012; 61
Lheureux, Penaloza, Zahir, Gris (CR49) 2005; 9
Aguer (CR46) 2015; 29
Kriisa (CR23) 2017; 16
Grimm, Kaiser, Plichta, Tobler (CR4) 2017; 75
Sun (CR18) 2016; 39
Xu (CR31) 2013; 11
Zheng (CR33) 2013; 12
Evangeliou, Vlassopoulos (CR47) 2003; 4
TR Koves (353_CR50) 2008; 7
P Schonfeld (353_CR13) 2016; 57
SV Pande (353_CR42) 1975; 72
JK Ho (353_CR38) 2002; 43
A Virmani (353_CR41) 2004; 25
J Bene (353_CR29) 2007; 98
PE Lheureux (353_CR48) 2009; 47
SS Signorelli (353_CR19) 2006; 23
B Kirkpatrick (353_CR8) 2012; 38
T Xu (353_CR31) 2013; 11
LL Jones (353_CR11) 2010; 49
C Ciacci (353_CR20) 2007; 39
O Grimm (353_CR4) 2017; 75
N Longo (353_CR52) 2016; 1863
A Annamalai (353_CR5) 2017; 8
FM Vaz (353_CR9) 2002; 361
J Shi (353_CR2) 2009; 460
CG Costa (353_CR12) 1997; 38
A Steiber (353_CR53) 2004; 25
L Sun (353_CR18) 2016; 39
CY Lai (353_CR34) 2017; 23
SM Wang (353_CR21) 2014; 53
M Cuturic (353_CR26) 2010; 16
C Aguer (353_CR46) 2015; 29
RE Frye (353_CR22) 2013; 3
DM Muoio (353_CR28) 2012; 15
RC Noland (353_CR14) 2009; 284
A Evangeliou (353_CR47) 2003; 4
F Boemer (353_CR55) 2017; 12
CT Cavedon (353_CR16) 2005; 51
MC Mutomba (353_CR40) 2000; 478
M Cuturic (353_CR24) 2016; 17
E Liepinsh (353_CR45) 2016; 473
P Zheng (353_CR33) 2013; 12
S Wong (353_CR17) 2013; 46
T Suvitaival (353_CR6) 2016; 6
WH Moos (353_CR43) 2016; 77
A Bruno (353_CR27) 2016; 39
A Coskun (353_CR10) 2002; 111
ME Lacruz (353_CR32) 2016; 9
CS Wijaya (353_CR36) 2018; 15
DH Chace (353_CR54) 2003; 49
OB Smeland (353_CR15) 2012; 61
AM Greenhalgh (353_CR7) 2017; 179
B Waagsbo (353_CR44) 2016; 46
MG Schooneman (353_CR51) 2013; 62
K Kriisa (353_CR23) 2017; 16
M Beckmann (353_CR39) 2016; 60
R Takizawa (353_CR35) 2014; 85
R Ensenauer (353_CR30) 2012; 53
S Saha (353_CR1) 2005; 2
H Jamilian (353_CR25) 2017; 33
PE Lheureux (353_CR49) 2005; 9
J Addington (353_CR3) 1999; 25
J Kerner (353_CR37) 2000; 1486
References_xml – volume: 53
  start-page: 1012
  year: 2012
  end-page: 1020
  ident: CR30
  article-title: In situ assay of fatty acid beta-oxidation by metabolite profiling following permeabilization of cell membranes
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.D022608
– volume: 38
  start-page: 280
  year: 2012
  end-page: 284
  ident: CR8
  article-title: Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbq058
– volume: 39
  start-page: 922
  year: 2007
  end-page: 928
  ident: CR20
  article-title: L-Carnitine in the treatment of fatigue in adult celiac disease patients: a pilot study
  publication-title: Dig. Liver. Dis.
  doi: 10.1016/j.dld.2007.06.013
– volume: 1486
  start-page: 1
  year: 2000
  end-page: 17
  ident: CR37
  article-title: Fatty acid import into mitochondria
  publication-title: Mol. Cell Biol. Lipids
  doi: 10.1016/S1388-1981(00)00044-5
– volume: 15
  start-page: 865
  year: 2018
  ident: CR36
  article-title: Differentiating medicated patients suffering from major depressive disorder from healthy controls by spot urine measurement of monoamines and steroid hormones
  publication-title: Int. J. Environ. Res. Public. Health
  doi: 10.3390/ijerph15050865
– volume: 25
  start-page: 173
  year: 1999
  end-page: 182
  ident: CR3
  article-title: Neurocognitive and social functioning in schizophrenia
  publication-title: Schizophr. Bull.
  doi: 10.1093/oxfordjournals.schbul.a033363
– volume: 9
  start-page: 487
  year: 2016
  end-page: 494
  ident: CR32
  article-title: Cardiovascular risk factors associated with blood metabolite concentrations and their alterations during a 4-year period in a population-based cohort
  publication-title: Circ. Cardiovasc Genet.
  doi: 10.1161/CIRCGENETICS.116.001444
– volume: 49
  start-page: 1797
  year: 2003
  end-page: 1817
  ident: CR54
  article-title: Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2003.022178
– volume: 11
  year: 2013
  ident: CR31
  article-title: Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study
  publication-title: BMC Med.
  doi: 10.1186/1741-7015-11-60
– volume: 25
  start-page: 455
  year: 2004
  end-page: 473
  ident: CR53
  article-title: Carnitine: a nutritional, biosynthetic, and functional perspective
  publication-title: Mol. Asp. Med.
  doi: 10.1016/j.mam.2004.06.006
– volume: 39
  start-page: 277
  year: 2016
  end-page: 280
  ident: CR27
  article-title: Acetyl-L-carnitine augmentation of clozapine in partial-responder schizophrenia: a 12-week, open-label uncontrolled preliminary study
  publication-title: Clin. Neuropharmacol.
  doi: 10.1097/WNF.0000000000000170
– volume: 15
  start-page: 595
  year: 2012
  end-page: 605
  ident: CR28
  article-title: Lipid-induced mitochondrial stress and insulin action in muscle
  publication-title: Cell. Metab.
  doi: 10.1016/j.cmet.2012.04.010
– volume: 361
  start-page: 417
  year: 2002
  end-page: 429
  ident: CR9
  article-title: Carnitine biosynthesis in mammals
  publication-title: Biochem. J.
  doi: 10.1042/bj3610417
– volume: 460
  start-page: 753
  year: 2009
  end-page: 757
  ident: CR2
  article-title: Common variants on chromosome 6p22.1 are associated with schizophrenia
  publication-title: Nature
– volume: 62
  start-page: 1
  year: 2013
  end-page: 8
  ident: CR51
  article-title: Acylcarnitines: reflecting or inflicting insulin resistance?
  publication-title: Diabetes
  doi: 10.2337/db12-0466
– volume: 6
  year: 2016
  ident: CR6
  article-title: Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2016.222
– volume: 46
  start-page: 408
  year: 2016
  end-page: 417
  ident: CR44
  article-title: Low levels of short- and medium-chain acylcarnitines in HIV-infected patients
  publication-title: Eur. J. Clin. Invest.
  doi: 10.1111/eci.12609
– volume: 53
  start-page: 30
  year: 2014
  end-page: 37
  ident: CR21
  article-title: A review of current evidence for acetyl-l-carnitine in the treatment of depression
  publication-title: J. Psychiatr. Res.
  doi: 10.1016/j.jpsychires.2014.02.005
– volume: 85
  start-page: 498
  year: 2014
  end-page: 507
  ident: CR35
  article-title: Neuroimaging-aided differential diagnosis of the depressive state
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2013.05.126
– volume: 2
  year: 2005
  ident: CR1
  article-title: A systematic review of the prevalence of schizophrenia
  publication-title: PLoS. Med.
  doi: 10.1371/journal.pmed.0020141
– volume: 57
  start-page: 943
  year: 2016
  end-page: 954
  ident: CR13
  article-title: Short- and medium-chain fatty acids in energy metabolism: the cellular perspective
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.R067629
– volume: 23
  start-page: 263
  year: 2006
  end-page: 270
  ident: CR19
  article-title: A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis
  publication-title: Drugs Aging
  doi: 10.2165/00002512-200623030-00008
– volume: 29
  start-page: 336
  year: 2015
  end-page: 345
  ident: CR46
  article-title: Acylcarnitines: potential implications for skeletal muscle insulin resistance
  publication-title: Faseb. J.
  doi: 10.1096/fj.14-255901
– volume: 9
  start-page: 431
  year: 2005
  end-page: 440
  ident: CR49
  article-title: Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?
  publication-title: Crit. Care.
  doi: 10.1186/cc3742
– volume: 16
  start-page: 3558
  year: 2017
  end-page: 3566
  ident: CR23
  article-title: Profiling of acylcarnitines in first episode psychosis before and after antipsychotic treatment
  publication-title: J. Proteome Res.
  doi: 10.1021/acs.jproteome.7b00279
– volume: 72
  start-page: 883
  year: 1975
  end-page: 887
  ident: CR42
  article-title: A mitochondrial carnitine acylcarnitine translocase system
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.72.3.883
– volume: 16
  start-page: 5
  year: 2010
  end-page: 14
  ident: CR26
  article-title: Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review
  publication-title: J. Psychiatr. Pract.
  doi: 10.1097/01.pra.0000367773.03636.d1
– volume: 47
  start-page: 101
  year: 2009
  end-page: 111
  ident: CR48
  article-title: Carnitine in the treatment of valproic acid-induced toxicity
  publication-title: Clin. Toxicol. (Phila.).
  doi: 10.1080/15563650902752376
– volume: 51
  start-page: 745
  year: 2005
  end-page: 752
  ident: CR16
  article-title: Age-related variations in acylcarnitine and free carnitine concentrations measured by tandem mass spectrometry
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2004.043646
– volume: 12
  start-page: 207
  year: 2013
  end-page: 214
  ident: CR33
  article-title: Identification and validation of urinary metabolite biomarkers for major depressive disorder
  publication-title: Mol. & Cell. Proteom.: MCP
  doi: 10.1074/mcp.M112.021816
– volume: 284
  start-page: 22840
  year: 2009
  end-page: 22852
  ident: CR14
  article-title: Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.032888
– volume: 43
  start-page: 1429
  year: 2002
  end-page: 1439
  ident: CR38
  article-title: Interactions of acyl carnitines with model membranes: a (13)C-NMR study
  publication-title: J. Lipid Res
  doi: 10.1194/jlr.M200137-JLR200
– volume: 7
  start-page: 45
  year: 2008
  end-page: 56
  ident: CR50
  article-title: Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance
  publication-title: Cell. Metab.
  doi: 10.1016/j.cmet.2007.10.013
– volume: 39
  start-page: 1563
  year: 2016
  end-page: 1570
  ident: CR18
  article-title: Early prediction of developing type 2 diabetes by plasma acylcarnitines: a population-based study
  publication-title: Diabetes Care
  doi: 10.2337/dc16-0232
– volume: 77
  start-page: 53
  year: 2016
  end-page: 72
  ident: CR43
  article-title: Epigenetic treatment of neuropsychiatric disorders: autism and schizophrenia
  publication-title: Drug. Dev. Res.
  doi: 10.1002/ddr.21295
– volume: 75
  start-page: 91
  year: 2017
  end-page: 103
  ident: CR4
  article-title: Altered reward anticipation: potential explanation for weight gain in schizophrenia?
  publication-title: Neurosci. Biobehav. Rev.
  doi: 10.1016/j.neubiorev.2017.01.029
– volume: 111
  start-page: 211
  year: 2002
  end-page: 223
  ident: CR10
  article-title: Liver L-carnitine biosynthesis in non-pregnant, pregnant and lactating rabbits
  publication-title: Res. Commun. Mol. Pathol. Pharmacol.
– volume: 61
  start-page: 100
  year: 2012
  end-page: 107
  ident: CR15
  article-title: Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice
  publication-title: Neurochem. Int.
  doi: 10.1016/j.neuint.2012.04.008
– volume: 33
  start-page: 442
  year: 2017
  end-page: 447
  ident: CR25
  article-title: Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
  publication-title: Gynecol. Endocrinol.
  doi: 10.1080/09513590.2017.1290071
– volume: 38
  start-page: 173
  year: 1997
  end-page: 182
  ident: CR12
  article-title: Quantitative analysis of plasma acylcarnitines using gas chromatography chemical ionization mass fragmentography
  publication-title: J. Lipid Res.
– volume: 17
  start-page: 475
  year: 2016
  end-page: 479
  ident: CR24
  article-title: Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study
  publication-title: World J. Biol. Psychiatry
  doi: 10.1080/15622975.2016.1178803
– volume: 23
  start-page: 324
  year: 2017
  end-page: 330
  ident: CR34
  article-title: Functional near-infrared spectroscopy in psychiatry
  publication-title: BJPsych Adv.
  doi: 10.1192/apt.bp.115.015610
– volume: 4
  start-page: 211
  year: 2003
  end-page: 219
  ident: CR47
  article-title: Carnitine metabolism and deficit--when supplementation is necessary?
  publication-title: Curr. Pharm. Biotechnol.
  doi: 10.2174/1389201033489829
– volume: 46
  start-page: 180
  year: 2013
  end-page: 183
  ident: CR17
  article-title: Acylcarnitine profile in thyroid disease
  publication-title: Clin. Biochem.
  doi: 10.1016/j.clinbiochem.2012.10.006
– volume: 478
  start-page: 19
  year: 2000
  end-page: 25
  ident: CR40
  article-title: Regulation of the activity of caspases by L-carnitine and palmitoylcarnitine
  publication-title: FEBS Lett.
  doi: 10.1016/S0014-5793(00)01817-2
– volume: 8
  start-page: 390
  year: 2017
  end-page: 396
  ident: CR5
  article-title: Prevalence of obesity and diabetes in patients with schizophrenia
  publication-title: World J. Diabetes
  doi: 10.4239/wjd.v8.i8.390
– volume: 179
  start-page: 57
  year: 2017
  end-page: 63
  ident: CR7
  article-title: Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naive patients with nonaffective psychosis
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2016.09.026
– volume: 3
  year: 2013
  ident: CR22
  article-title: Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2012.143
– volume: 49
  start-page: 61
  year: 2010
  end-page: 75
  ident: CR11
  article-title: Acylcarnitines: role in brain
  publication-title: Prog. Lipid Res.
  doi: 10.1016/j.plipres.2009.08.004
– volume: 25
  start-page: 533
  year: 2004
  end-page: 549
  ident: CR41
  article-title: Role of carnitine esters in brain neuropathology
  publication-title: Mol. Asp. Med.
  doi: 10.1016/j.mam.2004.06.003
– volume: 473
  start-page: 1191
  year: 2016
  end-page: 1202
  ident: CR45
  article-title: Long-chain acylcarnitines determine ischaemia/reperfusion-induced damage in heart mitochondria
  publication-title: Biochem. J.
  doi: 10.1042/BCJ20160164
– volume: 98
  start-page: 345
  year: 2007
  end-page: 350
  ident: CR29
  article-title: Plasma carnitine ester profiles in Crohn’s disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes
  publication-title: Br. J. Nutr.
  doi: 10.1017/S0007114507705020
– volume: 1863
  start-page: 2422
  year: 2016
  end-page: 2435
  ident: CR52
  article-title: Carnitine transport and fatty acid oxidation
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbamcr.2016.01.023
– volume: 12
  year: 2017
  ident: CR55
  article-title: Acylcarnitines profile best predicts survival in horses with atypical myopathy
  publication-title: PLoS. ONE.
  doi: 10.1371/journal.pone.0182761
– volume: 60
  start-page: 444
  year: 2016
  end-page: 457
  ident: CR39
  article-title: Changes in the human plasma and urinary metabolome associated with acute dietary exposure to sucrose and the identification of potential biomarkers of sucrose intake
  publication-title: Mol. Nutr. Food Res.
  doi: 10.1002/mnfr.201500495
– volume: 15
  start-page: 595
  year: 2012
  ident: 353_CR28
  publication-title: Cell. Metab.
  doi: 10.1016/j.cmet.2012.04.010
– volume: 4
  start-page: 211
  year: 2003
  ident: 353_CR47
  publication-title: Curr. Pharm. Biotechnol.
  doi: 10.2174/1389201033489829
– volume: 43
  start-page: 1429
  year: 2002
  ident: 353_CR38
  publication-title: J. Lipid Res
  doi: 10.1194/jlr.M200137-JLR200
– volume: 11
  year: 2013
  ident: 353_CR31
  publication-title: BMC Med.
  doi: 10.1186/1741-7015-11-60
– volume: 23
  start-page: 263
  year: 2006
  ident: 353_CR19
  publication-title: Drugs Aging
  doi: 10.2165/00002512-200623030-00008
– volume: 51
  start-page: 745
  year: 2005
  ident: 353_CR16
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2004.043646
– volume: 23
  start-page: 324
  year: 2017
  ident: 353_CR34
  publication-title: BJPsych Adv.
  doi: 10.1192/apt.bp.115.015610
– volume: 39
  start-page: 277
  year: 2016
  ident: 353_CR27
  publication-title: Clin. Neuropharmacol.
  doi: 10.1097/WNF.0000000000000170
– volume: 1863
  start-page: 2422
  year: 2016
  ident: 353_CR52
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbamcr.2016.01.023
– volume: 38
  start-page: 173
  year: 1997
  ident: 353_CR12
  publication-title: J. Lipid Res.
  doi: 10.1016/S0022-2275(20)37286-2
– volume: 60
  start-page: 444
  year: 2016
  ident: 353_CR39
  publication-title: Mol. Nutr. Food Res.
  doi: 10.1002/mnfr.201500495
– volume: 38
  start-page: 280
  year: 2012
  ident: 353_CR8
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbq058
– volume: 53
  start-page: 1012
  year: 2012
  ident: 353_CR30
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.D022608
– volume: 62
  start-page: 1
  year: 2013
  ident: 353_CR51
  publication-title: Diabetes
  doi: 10.2337/db12-0466
– volume: 29
  start-page: 336
  year: 2015
  ident: 353_CR46
  publication-title: Faseb. J.
  doi: 10.1096/fj.14-255901
– volume: 47
  start-page: 101
  year: 2009
  ident: 353_CR48
  publication-title: Clin. Toxicol. (Phila.).
  doi: 10.1080/15563650902752376
– volume: 361
  start-page: 417
  year: 2002
  ident: 353_CR9
  publication-title: Biochem. J.
  doi: 10.1042/bj3610417
– volume: 284
  start-page: 22840
  year: 2009
  ident: 353_CR14
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.032888
– volume: 16
  start-page: 5
  year: 2010
  ident: 353_CR26
  publication-title: J. Psychiatr. Pract.
  doi: 10.1097/01.pra.0000367773.03636.d1
– volume: 16
  start-page: 3558
  year: 2017
  ident: 353_CR23
  publication-title: J. Proteome Res.
  doi: 10.1021/acs.jproteome.7b00279
– volume: 33
  start-page: 442
  year: 2017
  ident: 353_CR25
  publication-title: Gynecol. Endocrinol.
  doi: 10.1080/09513590.2017.1290071
– volume: 85
  start-page: 498
  year: 2014
  ident: 353_CR35
  publication-title: Neuroimage
  doi: 10.1016/j.neuroimage.2013.05.126
– volume: 39
  start-page: 922
  year: 2007
  ident: 353_CR20
  publication-title: Dig. Liver. Dis.
  doi: 10.1016/j.dld.2007.06.013
– volume: 17
  start-page: 475
  year: 2016
  ident: 353_CR24
  publication-title: World J. Biol. Psychiatry
  doi: 10.1080/15622975.2016.1178803
– volume: 98
  start-page: 345
  year: 2007
  ident: 353_CR29
  publication-title: Br. J. Nutr.
  doi: 10.1017/S0007114507705020
– volume: 9
  start-page: 487
  year: 2016
  ident: 353_CR32
  publication-title: Circ. Cardiovasc Genet.
  doi: 10.1161/CIRCGENETICS.116.001444
– volume: 53
  start-page: 30
  year: 2014
  ident: 353_CR21
  publication-title: J. Psychiatr. Res.
  doi: 10.1016/j.jpsychires.2014.02.005
– volume: 15
  start-page: 865
  year: 2018
  ident: 353_CR36
  publication-title: Int. J. Environ. Res. Public. Health
  doi: 10.3390/ijerph15050865
– volume: 6
  year: 2016
  ident: 353_CR6
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2016.222
– volume: 25
  start-page: 533
  year: 2004
  ident: 353_CR41
  publication-title: Mol. Asp. Med.
  doi: 10.1016/j.mam.2004.06.003
– volume: 46
  start-page: 408
  year: 2016
  ident: 353_CR44
  publication-title: Eur. J. Clin. Invest.
  doi: 10.1111/eci.12609
– volume: 75
  start-page: 91
  year: 2017
  ident: 353_CR4
  publication-title: Neurosci. Biobehav. Rev.
  doi: 10.1016/j.neubiorev.2017.01.029
– volume: 12
  start-page: 207
  year: 2013
  ident: 353_CR33
  publication-title: Mol. & Cell. Proteom.: MCP
  doi: 10.1074/mcp.M112.021816
– volume: 9
  start-page: 431
  year: 2005
  ident: 353_CR49
  publication-title: Crit. Care.
  doi: 10.1186/cc3742
– volume: 25
  start-page: 173
  year: 1999
  ident: 353_CR3
  publication-title: Schizophr. Bull.
  doi: 10.1093/oxfordjournals.schbul.a033363
– volume: 39
  start-page: 1563
  year: 2016
  ident: 353_CR18
  publication-title: Diabetes Care
  doi: 10.2337/dc16-0232
– volume: 72
  start-page: 883
  year: 1975
  ident: 353_CR42
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.72.3.883
– volume: 2
  year: 2005
  ident: 353_CR1
  publication-title: PLoS. Med.
  doi: 10.1371/journal.pmed.0020141
– volume: 25
  start-page: 455
  year: 2004
  ident: 353_CR53
  publication-title: Mol. Asp. Med.
  doi: 10.1016/j.mam.2004.06.006
– volume: 179
  start-page: 57
  year: 2017
  ident: 353_CR7
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2016.09.026
– volume: 49
  start-page: 1797
  year: 2003
  ident: 353_CR54
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2003.022178
– volume: 46
  start-page: 180
  year: 2013
  ident: 353_CR17
  publication-title: Clin. Biochem.
  doi: 10.1016/j.clinbiochem.2012.10.006
– volume: 111
  start-page: 211
  year: 2002
  ident: 353_CR10
  publication-title: Res. Commun. Mol. Pathol. Pharmacol.
– volume: 49
  start-page: 61
  year: 2010
  ident: 353_CR11
  publication-title: Prog. Lipid Res.
  doi: 10.1016/j.plipres.2009.08.004
– volume: 478
  start-page: 19
  year: 2000
  ident: 353_CR40
  publication-title: FEBS Lett.
  doi: 10.1016/S0014-5793(00)01817-2
– volume: 57
  start-page: 943
  year: 2016
  ident: 353_CR13
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.R067629
– volume: 12
  year: 2017
  ident: 353_CR55
  publication-title: PLoS. ONE.
  doi: 10.1371/journal.pone.0182761
– volume: 460
  start-page: 753
  year: 2009
  ident: 353_CR2
  publication-title: Nature
  doi: 10.1038/nature08192
– volume: 77
  start-page: 53
  year: 2016
  ident: 353_CR43
  publication-title: Drug. Dev. Res.
  doi: 10.1002/ddr.21295
– volume: 61
  start-page: 100
  year: 2012
  ident: 353_CR15
  publication-title: Neurochem. Int.
  doi: 10.1016/j.neuint.2012.04.008
– volume: 7
  start-page: 45
  year: 2008
  ident: 353_CR50
  publication-title: Cell. Metab.
  doi: 10.1016/j.cmet.2007.10.013
– volume: 8
  start-page: 390
  year: 2017
  ident: 353_CR5
  publication-title: World J. Diabetes
  doi: 10.4239/wjd.v8.i8.390
– volume: 1486
  start-page: 1
  year: 2000
  ident: 353_CR37
  publication-title: Mol. Cell Biol. Lipids
  doi: 10.1016/S1388-1981(00)00044-5
– volume: 473
  start-page: 1191
  year: 2016
  ident: 353_CR45
  publication-title: Biochem. J.
  doi: 10.1042/BCJ20160164
– volume: 3
  year: 2013
  ident: 353_CR22
  publication-title: Transl. Psychiatry
  doi: 10.1038/tp.2012.143
SSID ssj0000548171
Score 2.4201512
Snippet Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 19
SubjectTerms 101/58
692/53/2421
692/699/476/1799
Adult
Behavioral Sciences
Bioenergetics
Biological Psychology
Biomarkers - blood
Carnitine - analogs & derivatives
Carnitine - blood
Case-Control Studies
China
Chromatography, Liquid
Energy Metabolism
Female
Humans
Logistic Models
Male
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Neurosciences
Pharmacotherapy
Psychiatry
Schizophrenia
Schizophrenia - blood
Schizophrenia - metabolism
Schizophrenia - therapy
Tandem Mass Spectrometry
SummonAdditionalLinks – databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEB9kD_x4ED_P6ikRfPIItpukSX1bDo9j4XzRg3srSZPiYWkX20XPv96ZbjfesnDia_PVZPLxm8zMLwDvKlR7lKwDR_BtuZz7gtvaUBhXMNKKNNQZBTiff87PLuTyUl1OPNsUC7Njvx-pu3vcZikMLKNQMCU4AsYDg_PSzOBgsVh-WcYrFUQfJtPZ1nYpzIe9srunzx6k3PeMjObRB3Bv3a7s9U_bNDdOoNNH8HCCjmyxkfVjuBPaJ3D3fDKOP4XvJ5F8-TdWxmx13fCKbj4GTGfuqiNnjZHIs2eIVVl_0-HuI7Os6ej1orWnl7IY-Ycw23q26vqBR4d0NhLSPoOL009fT8749JYCr6ROB26Vx4E3pq61C4hRQp5qrW0odNBBSDXHdVr5oI2zwmudeuOUrXMfcPtzpgriOczarg0vgOWVwWMfPymrpNMeNTanrSqkK9KAgkkg3Y5xWU1E4_TeRVOOBm9hyo1YShRLSWIpfyXwPhZZbVg2bst8tBVcOS24vpxnuSGuvMIk8DYm41Ih-4dtQ7emPLj5oMqW5wkcbuQcW0PNSZGyloDemQExA9Fw76a0V99GOu5cCGxbJnC8nSt_f-uWThzH6fTvLr_8r7pfwX2EdeQGxzN9BLPhxzq8Rug0uDfTkvkDJIIVDA
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEB7SDfRx6PvhNi0q9NSgrb22LLm3EBpCIaGHbklPRrJkEmLspbZpkl_fGb-a7UJKrtYYWfJo_I3nmxmADxm6PSLKHUfwrXm0sAnXuaI0LqciHfouDyjB-eg4PlxGX0_EyRaIMRemI-13JS07Mz2ywz7VaGwpGSyghDAR8ov5yuZ3YDsWCMFnsL08_rb3kxrJBYL-9yk1RjBDtXnv-jdoA1hu8iOnIOkDuNeWK335WxfFte_QwSP4Ma6gp5-cz9vGzLOrf4o73nqJj-HhgEzZXi_4BLZc-RTuHg2x92dwvj_Vdr7Cp2Q6uyx4Rj9WGhxn5qwiLkg3Y80QCrP6Op_vM9OsqKg5UmupERcj-gnTpWWrqm74xHdnXb3b57A8-PJ9_5APrRp4Fkm_4VpYfK9K5bk0DiGQi30ppXaJdNKFkVigGcisk8ro0ErpW2WEzmPr0LoalbnwBczKqnSvgMWZQlSBl4QWkZEWHUIjtUgik_gO7ZEH_vjy0myoY07tNIq0i6eHKu03MsWNTGkj0wsPPk63rPoiHjcJ74wakQ7nuU4XQayoFF-iPHg_DeNJpPCKLl3VkgzaNvQI49iDl70CTbOhYybIF_RArqnWJEBVvtdHyrPTrtp3HIY4d-TB7qiEfx_rhkXsTnr6_yW_vpX0G7iPqJFYdjyQOzBrfrXuLSKzxrwbzuEfnbQ3uw
  priority: 102
  providerName: Unpaywall
Title Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study
URI https://link.springer.com/article/10.1038/s41398-018-0353-x
https://www.ncbi.nlm.nih.gov/pubmed/30655505
https://www.proquest.com/docview/2168160798
https://www.proquest.com/docview/2179409666
https://pubmed.ncbi.nlm.nih.gov/PMC6336814
https://www.nature.com/articles/s41398-018-0353-x.pdf
UnpaywallVersion publishedVersion
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central Free
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVAQT
  databaseName: Springer Nature - nature.com Journals - Fully Open Access
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: NAO
  dateStart: 20110401
  isFulltext: true
  titleUrlDefault: https://www.nature.com/siteindex/index.html
  providerName: Nature Publishing
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: AAJSJ
  dateStart: 20110401
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 2158-3188
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000548171
  issn: 2158-3188
  databaseCode: C6C
  dateStart: 20110401
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9swED_aBPbxMPbVzVsXNNjTiqgdW5Y8GCMLLSXQULYFsicjWzIrM3Y2O6zdX787x3YbCtmrJFuW7nS-0939DuBdimaPCDLLUfnWPBibiOtMURqXVYH2XZt5lOB8Pg_PFsFsKZZ7MO9yYSisspOJjaA2ZUp35MdjL1QEhhapT6tfnKpGkXe1K6Gh29IK5mMDMbYPwzEhYw1g-PlkfvGlv3VBBUV50uvcm746rlCKU5aZR5lmwudX2z-oO1rn3eDJ3oP6EO6vi5W-_qPz_NZP6vQxPGq1SzbZsMMT2LPFU7h33vrPn8HPaY_P_BdfxnR6nfOULkdq7GfJZUnxHA3WZ8VQnWXV7Zi8D0yzvKQCR2tDxbQYhZAwXRi2Kqua9zHrrMGsfQ6L05Nv0zPellvgaSDdmmthkDZKZZlMLKoxFndbSm0jaaX1AzHGo5waK1WifSOla1QidBYaixIyUan1D2BQlIV9CSxMFWoG2CS0CBJp0KhLpBZRkESuRZnigNvtcZy2WORUEiOPG5-4r-INWWIkS0xkia8ceN8_stoAcewafNgRLm7PZBXfcJADb_tuPE3kItGFLdc0BuUTWnVh6MCLDZ372dC4EmTPOSC3OKAfQEjd2z3F5Y8GsTv0fZw7cOCo45Wbz9qxiKOenf6_5Fe7l_waHqCqR6Fx3JOHMKh_r-0bVKfqZAT7cilHMJxMZl9no_bEYOs0nI6aKwpsW8wvJt__AbbHJsA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9QwDLfGJjF4QHxTGBAkeGGK1o-0SZEmBGPTje1OCG3S3rq0ScVE1R70Ttvxx_G3YffabqdJx9Nem7RpYsexY_tngLcZmj2hyC1H5Vtz4ZuY61xRGpdVQgeuzT1KcB6OosGx-HoSnqzA3y4XhsIqO5nYCGpTZXRHvuV7kSIwtFh9HP_iVDWKvKtdCQ3dllYw2w3EWJvYcWBn52jC1dv7X5De73x_b_doZ8DbKgM8E9KdcB0a_CWl8lymFk9vi4NIqW0srbSBCH3k4MxYqVIdGCldo9JQ55GxKBhSldkAv3sL1kQgYjT-1j7vjr597295UCFSnvQ6d2qgtmo8NSirzaPMtjDgF4sH4jUt93qwZu-xvQvr03KsZ-e6KK4cinv34V6rzbJPc_Z7ACu2fAi3h62__hH83OnxoP_gx5jOZgXP6DJmgu0sPasofqTBFq0Zqs-svhoD-IFpVlRUUGlqqHgXo5AVpkvDxlU94X2MPGswch_D8Y0s_BNYLavSPgMWZQo1EXwU6lCk0qARmUodxiKNXYsyzAG3W-Mka7HPqQRHkTQ--EAlc7IkSJaEyJJcOPC-f2U8B_5Y1nmjI1zSyoA6ueRYB970zbh7ySWjS1tNqQ_KQ7Qio8iBp3M696OhMReS_eiAXOCAvgMhgy-2lGc_GoTwKAhwbOHAZscrl7-1ZBKbPTv9f8rPl0_5NawPjoaHyeH-6OAF3EE1k8LyuCc3YHXye2pfoio3SV-1-4XB6U1v0X8DP2Aj
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIhU4IN4NFDASXKisTeIkdpAQQi2rltKKA5X2ljqxI6pGyUKyapefxq9jJpukXVVaTr2uvXGceXjG880MwNsM3Z4wyC1H41vzwDcx17miNC6rAi1cm3uU4Hx4FO0dB18n4WQN_va5MASr7HViq6hNldEd-cj3IkXF0GI1yjtYxPfd8afpL04dpCjS2rfTWLDIgZ2fo_tWf9zfRVq_8_3xlx87e7zrMMCzQLoN16HB11Eqz2Vq8eS2uICU2sbSSiuC0EfuzYyVKtXCSOkalYY6j4xFpZCqzAp87i24LYWICU4oJ3K430FTSHnS6wOpQo1qPC8on82jnLZQ8Ivlo_CafXsdpjnEau_BnVk51fNzXRRXjsPxA7jf2bHs84LxHsKaLR_BxmEXqX8MZztDJeg_-DCms3nBM7qGaXCcpacVIUfaqqI1Q8OZ1VfRfx-YZkVFrZRmhtp2MQKrMF0aNq3qhg_oeNZWx30Cxzfy2Z_CelmVdhNYlCm0QfCnUIdBKg26j6nUYRyksWtRezng9t84ybqq59R8o0ja6LtQyYIsCZIlIbIkFw68H_4yXZT8WDV5qydc0kl_nVzyqgNvhmGUWwrG6NJWM5qDmhD9xyhy4NmCzsNq6MaF5Dk6IJc4YJhANcGXR8rTn21t8EgIXDtwYLvnlcvXWrGJ7YGd_r_l56u3_Bo2UDCTb_tHBy_gLtqXhMfjntyC9eb3zL5EG65JX7XCwuDkpqXzH3HuXb0
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEB7SDfRx6PvhNi0q9NSgrb22LLm3EBpCIaGHbklPRrJkEmLspbZpkl_fGb-a7UJKrtYYWfJo_I3nmxmADxm6PSLKHUfwrXm0sAnXuaI0LqciHfouDyjB-eg4PlxGX0_EyRaIMRemI-13JS07Mz2ywz7VaGwpGSyghDAR8ov5yuZ3YDsWCMFnsL08_rb3kxrJBYL-9yk1RjBDtXnv-jdoA1hu8iOnIOkDuNeWK335WxfFte_QwSP4Ma6gp5-cz9vGzLOrf4o73nqJj-HhgEzZXi_4BLZc-RTuHg2x92dwvj_Vdr7Cp2Q6uyx4Rj9WGhxn5qwiLkg3Y80QCrP6Op_vM9OsqKg5UmupERcj-gnTpWWrqm74xHdnXb3b57A8-PJ9_5APrRp4Fkm_4VpYfK9K5bk0DiGQi30ppXaJdNKFkVigGcisk8ro0ErpW2WEzmPr0LoalbnwBczKqnSvgMWZQlSBl4QWkZEWHUIjtUgik_gO7ZEH_vjy0myoY07tNIq0i6eHKu03MsWNTGkj0wsPPk63rPoiHjcJ74wakQ7nuU4XQayoFF-iPHg_DeNJpPCKLl3VkgzaNvQI49iDl70CTbOhYybIF_RArqnWJEBVvtdHyrPTrtp3HIY4d-TB7qiEfx_rhkXsTnr6_yW_vpX0G7iPqJFYdjyQOzBrfrXuLSKzxrwbzuEfnbQ3uw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterizing+acyl-carnitine+biosignatures+for+schizophrenia%3A+a+longitudinal+pre-+and+post-treatment+study&rft.jtitle=Translational+psychiatry&rft.au=Cao%2C+Bing&rft.au=Wang%2C+Dongfang&rft.au=Pan%2C+Zihang&rft.au=Brietzke%2C+Elisa&rft.date=2019-01-17&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2158-3188&rft.volume=9&rft_id=info:doi/10.1038%2Fs41398-018-0353-x&rft_id=info%3Apmid%2F30655505&rft.externalDocID=PMC6336814
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2158-3188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2158-3188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2158-3188&client=summon